Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1137820190400010007
ÀÇ°øÇÐȸÁö
2019 Volume.40 No. 1 p.7 ~ p.14
Poly(¥å-caprolactone) Microcapsule with Encapsulated Nifedipine Prepared by Magnetic Stirrer
Lee Hye-Ran

Lee Deuk-Yong
Song Yo-Seung
Kim Bae-Yeon
Abstract
The microencapsulation of nifedipine (NF) with 4 wt% of poly(¥å-caprolactone) (PCL)/polyvinylpyrollidone (PVP) or PCL/polyethylene glycol (PEG) was carried out by solvent evaporation method in oil in water emulsion system to investigate the effect of PVP and PEG addition on drug release behavior of the microcapsules. The PVA (emulsifier) concentration of 1.0 wt% was chosen for the formation of PCL capsule having an average size of 154 ¡¾ 25 ¥ìm due to nearly spherical shape with a narrow size distribution. As PCL/PVP and PCL/PEG ratios were raised from 10/0 to 6/4, the capsule size increased gradually from 154 ¡¾ 25 ¥ìm to 236 ¡¾ 32 ¥ìm and 248 ¡¾ 56 ¥ìm, respectively. The drug release rate of PCL/PVP and PCL/PEG capsules increased dramatically from 0 to 4 h at the beginning and then reached the plateau region from 20 h. As the concentration of PVP or PEG increased, the amount of drug release increased, suggesting that the larger capsule size was attributed to the higher drug content. However, the drug release behavior remained almost constant. The PCL capsules exhibited no evidence of causing cell lysis or toxicity regardless of NF loading, implying that the microcapsules are clinically suitable for use as drug delivery systems.
KEYWORD
Poly(¥å-caprolactone) (PCL), Polyvinylpyrollidone (PVP), Polyethylene glycol (PEG), Polyvinyl alcohol (PVA), Nifedipine, Microcapsule, Drug release, Cytotoxicity
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) ´ëÇÑÀÇÇÐȸ ȸ¿ø